PaxMedica, Inc.

Equities

PXMD

US70424C2035

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:57:13 2024-05-30 EDT			5-day change	1st Jan Change
0.36 ^USD	+11.80%		+30.91%	-52.44%

05-13	PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-06	PaxMedica, Inc.(NasdaqCM:PXMD) dropped from S&P TMI Index	CI

PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 06:17 am

PaxMedica, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 14.8 million compared to USD 10.23 million a year ago. Basic loss per share from continuing operations was USD 28.73 compared to USD 26.01 a year ago.

Latest news about PaxMedica, Inc.

PaxMedica, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
PaxMedica, Inc.(NasdaqCM:PXMD) dropped from S&P TMI Index	05-05	CI
PaxMedica, Inc.(NasdaqCM:PXMD) dropped from NASDAQ Composite Index	04-30	CI
Paxmedica, Inc. Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101	04-23	CI
PaxMedica, Inc. Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness	04-16	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	04-12	MT
Top Midday Gainers	04-12	MT
Major US Banks' Lower Earnings Drag Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday	04-12	MT
PaxMedica, Inc. Achieves Key Milestone in the Development of Pax-101 and Provides Update on Potential NDA Submission	04-11	CI
PaxMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Certain Warrants of PaxMedica, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	02-18	CI
Certain Common Stock of PaxMedica, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.	02-18	CI
HC Wainwright Starts PaxMedica With Buy Rating, $3 Price Target	12-04	MT
PaxMedica Raises $7 Million From Public Offering	11-22	MT
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	11-20	MT
Top Midday Decliners	11-20	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	11-20	MT
PaxMedica Prices $7 Million Public Offering of Shares, Warrants; Stock Slumps	11-20	MT
PaxMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Sector Update: Health Care Stocks Rise Late Afternoon	11-07	MT
Top Midday Gainers	11-07	MT
PaxMedica, Inc. acquired Certain Suramin Research Assets from Rediscovery Life Sciences AKI LLC for $0.1 million.	23-10-30	CI
PaxMedica Undertakes 1-for-17 Reverse Stock Split	23-10-30	MT
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	23-10-26	MT
Paxmedica, Inc. Holds Important Fda Type-B Meeting to Review Pax-101 Pivotal Trial Data	23-10-26	CI

Chart PaxMedica, Inc.

Duration

Period

More charts

Company Profile

PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.322 USD

Average target price

3 USD

Spread / Average Target

+831.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PAXMEDICA, INC.	-52.44%	2.51M
MODERNA, INC.	+52.36%	56.69B
IQVIA HOLDINGS INC.	-3.86%	41B
LONZA GROUP AG	+38.14%	38.11B
CELLTRION, INC.	-12.01%	26.89B
ICON PUBLIC LIMITED COMPANY	+14.13%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.62%	18.59B
BIO-TECHNE CORPORATION	+0.21%	12.39B
MEDPACE HOLDINGS, INC.	+25.96%	11.99B
UNITED THERAPEUTICS CORPORATION	+23.02%	11.88B

Other Biotechnology & Medical Research